

<b>Studies in ARDS</b>	<b>N° of patients</b>	<b>Type of corticosteroids</b>	<b>Primary outcome</b>	<b>p-value mortality</b>
Beranard	99	Methylprednisolone		
Meduri	24	Methylprednisolone	Improvement in lung function and mortality.	0.03
Confalonieri	46	Hydrocortisone	Improvement in P/F	0.49
Steinberg	180	Methylprednisolone	Mortality at 60-days	1
Annane	177	Hydrocortisone	28-day survival	NS
meduri	91	Methylprednisolone	1-point reduction in lung injury score (LIS) or successful extubation by day 7.	0.21
Tongyoo	197	Hydrocortisone	28-day all-cause mortality	0.46
Villar	217	Dexamethasone	Ventilator free days at 28-day	0.0047
<b>Studies in COVID-19</b>	<b>N° of patients</b>	<b>Type of corticosteroids</b>	<b>Main outcome</b>	<b>p-value mortality</b>
Tomazini	299	Dexamethasone	Ventilator free days at 28-day	0.31
Dequin	149	Methylprednisolone	Death at 21 days	0.057
Jeronimo	393	Methylprednisolone	28-day mortality	0.629
Horby	6425	Dexamethasone	28-day mortality	< 0.001
Angus	403	Hydrocortisone	Improvement organ support at 21 days	NA

Table S1: main characteristics of included studies. NA: not available, NS: non significant.